This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Quidel (QDEL) This Earnings Season?
by Zacks Equity Research
Quidel (QDEL) is expected to have gained from its Molecular Diagnostic Solutions business in Q1.
Livongo Health (LVGO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Livongo Health (LVGO) first-quarter performance to reflect growth in core Livongo for Diabetes solution.
What's in Store for AmerisourceBergen's (ABC) Q2 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results likely to reflect solid performance at Pharmaceutical Distribution.
What's in Store for Becton, Dickinson's (BDX) Q2 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) fiscal second-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.
OPKO Health (OPK) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) first-quarter performance is likely to reflect solid performance from Products and RAYALDEE.
Genetic Testing Likely to Drive Invitae's (NVTA) Q1 Earnings
by Zacks Equity Research
Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q1.
What's in the Cards for DaVita (DVA)This Earnings Season?
by Zacks Equity Research
DaVita (DVA) is expected to have gained from Kidney Care segment in Q1.
What's in Store for Varian Medical (VAR) in Q2 Earnings?
by Zacks Equity Research
Varian's (VAR) solid Oncology platform is expected to have driven fiscal second-quarter performance.
PerkinElmer (PKI) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results likely to reflect top-line growth and robust performance at Diagnostics segment. However, forex is likely to have remained a woe.
T2 Biosystems (TTOO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
T2 Biosystems' (TTOO) first-quarter performance is likely to reflect growth in product revenues.
Aurora Cannabis Inc. (ACB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed the most recent trading day at $0.75, moving -1.68% from the previous trading session.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) first-quarter performance to reflect focus on product innovation and R&D.
Humana (HUM) Gears up for Earnings in Q1: What to Expect
by Zacks Equity Research
Humana's (HUM) Q1 earnings results are likely to reflect growth in revenues, which in turn, are expected to have been driven by its Medicaid and Medicare businesses.
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed at $0.72 in the latest trading session, marking a -0.29% move from the prior day.
5 Recession-Proof Stocks to Buy Amid Coronavirus-Led Job Crisis
by Zacks Equity Research
Five recession-proof stocks that are poised to return well on investment amid this coronavirus-led job crisis.
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $0.75, marking a -1.42% move from the previous day.
Here's Why You Should Hold on to Luminex (LMNX) Stock Now
by Zacks Equity Research
Luminex (LMNX) continues to benefit from robust product portfolio, solid molecular diagnostics and ARIES platforms.
BD (BDX) Receives EUA for New Coronavirus Detection Test
by Zacks Equity Research
Becton, Dickinson (BDX) receives EUA from the FDA for another molecular diagnostic test for COVID-19, which can return results in two to three hours.
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed the most recent trading day at $0.80, moving -1.27% from the previous trading session.
Aurora Cannabis (ACB): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Aurora Cannabis (ACB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $0.91, marking a +1.97% move from the previous day.
Implied Volatility Surging for Aurora Cannabis (ACB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aurora Cannabis (ACB) stock based on the movements in the options market lately.
Here's How Coronavirus Can Impact Cannabis Industry
by Zacks Equity Research
Marijuana should be avoided during the pandemic as users share marijuana joints, which may increase the spread of the virus.
What Do Canopy Earnings Say About Cannabis ETFs?
by Sanghamitra Saha
Solid earnings drive Canopy Growth stock and boost the industry as a result. Is it right time to buy marijuana ETFs?
New Strong Sell Stocks for February 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today